Tratopedia
繁中
Settings

Text size

Language

Theme

High contrast

Version

v1.230.2

The release this page was built from. It is what the service worker caches under.

Slide deck

Back

Bruker’s spatial biology division: NanoString, Canopy and Acuity

Bruker built one spatial biology division from Canopy (bought 2020), Acuity (founded 2021) and NanoString, bought out of bankruptcy for $392.6 million in 2024. The breadth is real; the profit is unproven: two goodwill impairments followed, and no division revenue is disclosed.

  1. Research summary · 17 October 2026

    Bruker’s spatial biology map

    How NanoString, Canopy Biosciences and Acuity Spatial Genomics became one division, and where it stands

    Sources read 17 October 20261 / 15

  2. Basics

    What does spatial biology do?

    Not only which molecules are in a tissue, but where they are and what is next to them.

    • DNA

      How the genome folds

      • Where chromosomes and genes sit in the nucleus, in 3D.
      • At Bruker: PaintScape.
    • RNA

      Which genes are in use

      • Gene activity, with each cell’s position kept.
      • At Bruker: CosMx, GeoMx, nCounter.
    • Protein

      What does the work

      • The molecules that carry out a cell’s functions.
      • At Bruker: CellScape, plus GeoMx and CosMx panels.

    An analogy: blending a fruit salad tells you what was in it; spatial biology photographs the bowl first, then labels every piece.2 / 15

  3. Structure

    Four businesses, one division

    Bruker Spatial Biology, formed 9 October 2024, sits in Bruker’s BSI NANO segment. Its president is Todd Garland.

    BusinessBaseHow it joined
    NanoStringSeattle areabought out of bankruptcy, May 2024
    Canopy BiosciencesSt. Louisacquired, September 2020
    Bruker Spatial GenomicsSan Joseformerly Acuity; Bruker majority investment, 2021
    Bruker Cellular Analysis—formerly PhenomeX; merged in 1 April 2026

    “Bruker Spatial Genomics” is the renamed Acuity, not the division. Sources: Bruker release, 9 Oct 2024; Form 10-Q, Q2 2026.3 / 15

  4. NanoString, 2003–2013

    Counting RNA one barcode at a time

    1. 2003Incorporated, on technology conceived in Leroy Hood’s laboratories at the Institute for Systems Biology.
    2. 2004Exclusive worldwide licence: 13 patents and applications, low single-digit royalties.
    3. 2008First nCounter sold: up to 800 genes per run, counted directly.
    4. 2013Approved for listing on Nasdaq as NSTG; accumulated deficit already $102.8 million.
    5. Mar 2023About 1,130 nCounter systems installed; more than 6,820 papers.

    An analogy: each RNA gets its own coloured barcode, and the machine counts the barcodes. Position is lost; that came later. Sources: S-1/A, 2013; Form 10-Q, Q1 2023.4 / 15

  5. NanoString, the spatial turn

    GeoMx and CosMx

    Two instruments for two scales; AtoMx, the cloud software, launched with CosMx in December 2022.

    • 2019

      GeoMx DSP

      • The researcher selects regions of a tissue section; RNA and protein are profiled per region.
      • Now: whole transcriptome and more than 1,200 protein targets.
    • Dec 2022

      CosMx SMI

      • Single-cell and subcellular imaging of RNA and protein.
      • Since 2025: a human whole-transcriptome panel, over 18,000 transcripts, plus 64+ proteins on one section.

    An analogy: GeoMx circles a few districts on a map; CosMx is the satellite photo that shows who lives in each house. Sources: Form 10-Q, Q1 2023; Bruker releases, 2025 and 2026.5 / 15

  6. Litigation

    The patent war with 10x Genomics

    Four years across US, German and European patent courts.

    1. 6 May 202110x sues over GeoMx in Delaware.
    2. 17 May 2023Munich court enjoins CosMx RNA products in Germany.
    3. 19 Sep 2023Unified Patent Court preliminary injunction, 17 states.
    4. 17 Nov 2023Delaware jury: wilful infringement by GeoMx, about $31 million.
    5. 26 Feb 2024Appeal court lifts the UPC injunction; CosMx back in 16 countries.
    6. 23 Dec 2024US permanent injunction against GeoMx announced; earlier customers spared.
    7. 12 May 2025Global settlement: $68.0 million in four instalments, plus royalties for the life of the patents.

    Reading: the verdict, and the withdrawn guidance two days later, came eleven weeks before NanoString’s bankruptcy. Sources: 10x Form 8-K, May 2025, and Form 10-Q, Q1 2024; NanoString Form 8-K, Nov 2023.6 / 15

  7. 2023–2024

    Bankruptcy, and a buyer

    Revenue reached about $168 million in 2023; the losses did not close.

    • $127.3Mrevenue, 2022, against a net loss of $159.5M
    • $931.6Maccumulated deficit, 30 Sep 2023
    • $220Mstalking-horse bid, March 2024
    • $392.6MBruker’s winning cash bid, 78.4% higher
    • Two cuts: about 110 jobs in October 2023 and about 50 in December 2023.
    • Chapter 11 on 4 February 2024; auction on 16 April; closing on 6 May. Bruker also took on $44.7 million of litigation liability.

    Chapter 11 lets a company keep operating under court supervision and sell its assets to the best bidder. Sources: NanoString results and filings, 2023–2024; Bruker exhibit, Apr 2024.7 / 15

  8. Canopy Biosciences

    Seeing proteins in place

    Bought almost four years before NanoString; it brings the protein layer.

    1. Late 2016Founded in St. Louis by BioGenerator; chief executive Edward Weinstein.
    2. 2019A funding round pays for buying Zellkraftwerk, maker of a ChipCytometry instrument in use since 2016.
    3. 10 Sep 2020Bruker buys Canopy: $24.2 million, up to $5.0 million more.
    4. 3 Mar 2022CellScape launched, the next generation, designed with Bruker’s microscopy expertise.
    5. Feb 2026CellScape XR announced; shipments expected in summer 2026.

    An analogy: the same slide is stained, imaged and cleared again and again, one set of markers at a time, and the layers are stacked into one map. Sources: Bruker 10-Q, Q3 2020; BioSTL; Canopy release, 2022.8 / 15

  9. Acuity Spatial Genomics

    Seeing the genome in 3D

    The youngest piece; it brings the DNA layer.

    • March 2021: formed with a Bruker majority investment; Bruker NANO’s Mark Munch is chief executive; cofounders Huy Q. Nguyen and Shyamtanu Chattoraj.
    • Technology licensed from Ting Wu’s laboratory at Harvard Medical School, published in Nature Methods in 2020.
    • It sees chromosome folding, gene positions in the nucleus, and copy-number changes, in place.
    • PaintScape launched at AGBT in February 2025; pre-orders opened in 2026, with shipments expected from the second quarter of 2026.

    An analogy: DNA in the nucleus is not a straight line but a folded ball of wool; which strands touch affects which genes switch on. Sources: SelectScience, Mar 2021; Bruker releases, 2025 and 2026.9 / 15

  10. 9 October 2024

    Forming Bruker Spatial Biology

    Coordinate first; do not break the businesses up.

    • “Fit-for-purpose”: CosMx, GeoMx and CellScape keep their own teams. Munch: “The road to failure … is to try to make a Swiss Army knife.”
    • Each business stays where it was: Seattle, St. Louis, San Jose.
    • Leadership: Todd Garland, president; Joseph Beechem, NanoString’s founding chief scientific officer, held the title at the division in 2025.
    • 1 April 2026: Bruker Cellular Analysis joins. 1 July 2026: Bruker reorganises into four groups; the division’s segment is unchanged.

    An analogy: specialist shops brought into one department store, each counter still run by its own staff. Sources: Bruker release, 9 Oct 2024; GEN, 11 Oct 2024; Form 10-Q, Q2 2026.10 / 15

  11. Portfolio

    The product map today

    DNA, RNA, protein and live cells under one owner.

    PlatformMeasuresScale
    CosMxRNA and protein; human and mouse whole transcriptomesingle cell, subcellular
    GeoMxwhole transcriptome, 1,200+ proteinsselected regions
    CellScape XRhigh-plex proteinsubcellular
    PaintScape3D structure of DNAin the nucleus
    nCountergene expression, up to 800 genesbulk
    Beaconlive-cell functionsingle cell
    AtoMxcloud analysis, 3D AI segmentationsoftware

    2026: workflows linking GeoMx to CellScape XR and CellScape XR to CosMx on one tissue section; a Glasgow centre is to image 1,000+ pancreatic cancer samples. Sources: Bruker releases, Feb and Apr 2026.11 / 15

  12. Money

    Broad technology, unproven profit

    Bruker does not report the division’s revenue; this is what the filings do show.

    • $96.5Mgoodwill impairment, Q3 2025, division and an automation unit together
    • $36.5Mgoodwill impairment, Q2 2026, the division alone
    • $174.5Mdivision goodwill left after it
    • Target set in April 2024: NanoString “near break-even” by 2026. August 2026: the business “continued to experience operating losses”.
    • The $1.084 billion often quoted for 2025 is the whole BSI NANO segment, including X-ray, atomic force microscopy and semiconductor metrology; the division’s revenue is not disclosed.

    Goodwill is the premium paid over a business’s identifiable assets; an impairment writes it down when the business is worth less than its book value. Sources: Bruker 10-Qs, Q3 2025 and Q2 2026; exhibit, Apr 2024; Q2 2026 call.12 / 15

  13. Competition

    Who else is in the field

    10x Genomics is the litigant and the reference rival; Bruker’s case rests on breadth.

    CompanySpatial platformsScale
    10x GenomicsVisium HD, Xenium, Atera (shipping from Sep 2026)$642.8M revenue, 2025, incl. $46.1M licence and royalty
    Bruker Spatial BiologyCosMx, GeoMx, CellScape XR, PaintScape, nCounternot disclosed
    A diagnostics and reagents groupa diagnostics and spatial biology segment$336.4M segment, last fiscal year; $11.3B takeover announced
    A proteomics-imaging companymultiplex protein imaging$69.2M spatial revenue, 2025
    The largest private competitorimaging spatial transcriptomicsmore than $300M raised

    “CosMx has always led in plex” is Bruker’s claim; Atera now challenges CosMx’s whole-transcriptome position. No independent comparison was read. Sources: 10x 10-K, 2025; GEN, 9 Oct 2026; Zacks, 30 Sep 2026.13 / 15

  14. Outlook

    What is Bruker betting on?

    One market report puts spatial biology at ~$1.14 billion in 2026, growing ~17% a year; definitions differ between reports.

    • Opportunities

      What could work

      • Biopharma bookings across all of Bruker up more than 20% in Q2 2026.
      • Reading: one tissue passed between instruments could make the platforms hard to swap out.
      • Roadmap: CosMx miRNA and TCR assays; a 1000+-plex PaintScape cancer panel.
    • Risks

      What could go wrong

      • US academic funding: soft demand reported through Q2 2026.
      • 10x’s scale and Atera; the royalty on GeoMx and CosMx.
      • China: Bruker’s revenue there down 17.1% in the first half of 2026; further impairments, which Bruker’s 10-Q says may be incurred.

    Sources: Q2 2026 call; Bruker releases, 2026; Form 10-Q, Q2 2026; DeciBio, 2025.14 / 15

  15. In one slide

    The whole story

    NanoString fell to a patent war and years of losses and was bought by Bruker; Canopy and Acuity add the protein and DNA layers. The breadth is real; the profit is not yet shown.

    • Watch: Bruker’s third-quarter and full-year 2026 reports, for impairments and any word on break-even.
    • Watch: whether PaintScape, CellScape XR and the mouse whole-transcriptome assay are reported shipping.
    • Watch: the first published comparisons of Atera and CosMx on the same tissue.
    • Reading, for laboratories: the patent risk is gone; test on your own tissue and get consumables and software commitments in writing. For analysts: do not use the $1.084 billion as the division’s revenue.

    Bruker’s spatial biology division · sources read 17 October 202615 / 15